Paltimatrectinib

DB21588InvestigationalSmall molecule

Paltimatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Paltimatrectinib is a tropomyosin receptor kinase (TRK) inhibitor. Paltimatrectinib is under investigation... Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors).

Mechanism: Pharmacologically active on High affinity nerve growth factor receptor, BDNF/NT-3 growth factors receptor, and NT-3 growth factor receptor
Curator reviewed
Formula / weight: C₂₀H₁₅F₅N₆ · 434.374 g/mol (avg)
Code names: PBI-200 · PPI-5278

Resolves to

Compound

UNIISP4MKH8Y5JCAS2353522-15-1ChEMBLCHEMBL5095076

Structure

InChIKeyFYPXPQSPRRZJCK-MRXNPFEDSA-NSMILESFC1=CC([C@H]2CCCN2C2=NC3=C(C=NN3C=C2)N2C=C(C=N2)C(F)(F)F)=C(F)C=C1

Targets

P04629NTRK1Q16620NTRK2Q16288NTRK3

What you can answer from here — as of September 16, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Paltimatrectinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account